Clinical trials: sponsored by European Organisation for Research and Treatment of Cancer - EORTC
Medulloblastoma
Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma
Medulloblastoma is a rare brain malignancy, mainly affecting children. Treatment of this rapidly growing tumor begins with maximal surgical removal plus radiation and chemotherapy. Treatment toxicity is high.
- Trial name
- PersoMed-I (NCT04402073)
- Testing
- Sonidegib, Cisplatin, Lomustine
- Where
- 50 sites in Australia, Austria and 6 more
- Volunteers
- 20 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cancer
Assessing Patient-reported & Patient-related Outcomes in Randomized Cancer Trials for Older Adults
As older adults with cancer are underrepresented in randomized clinical trials (RCT), there is limited evidence on which to rely for treatment decisions for this population.
- Trial name
- DATECANelderly (NCT03676218)
- Testing
- Elderly cancer patients
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Institut Bergonié
MSI, ColoRectal Cancer
Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer
The primary objective of this study is to determine the anti-tumor activity, as measured by overall response rate (ORR) of atezolizumab in combination with bevacizumab in patients with chemotherapy resistant CRC and positivity…
- Conditions
- MSI, ColoRectal Cancer, Chemotherapy, Resistance, APC
- Trial name
- NCT02982694
- Testing
- Atezolizumab, Bevacizumab
- Where
- 7 sites in Belgium, Italy and 2 more
- Volunteers
- 46 people
- Sponsor
- Vall d'Hebron Institute of Oncology
Prostate Cancer
Phase III Radium 223 mCRPC-PEACE III
The primary objective of the trial is to assess if upfront combination of enzalutamide and Ra223 improves radiological progression-free survival (rPFS1) by investigator assessment compared to enzalutamide single agent in…
- Trial name
- PEACE III (NCT02194842)
- Testing
- Ra223, Enzalutamide
- Where
- 64 sites in Belgium, Brazil and 10 more
- Volunteers
- 446 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Malignant Pleural Mesothelioma
Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma
This is a multicenter, randomized, 1:1, double blinded phase II trial. Patients with unresectable malignant pleural mesothelioma (MPM) will be randomized between arm A: nintedanib and arm B:placebo
- Trial name
- NEMO (NCT02863055)
- Testing
- Nintedanib
- Where
- 9 sites in Belgium, Italy and 1 more
- Volunteers
- 37 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer
This is an open label non-comparative controlled randomized phase II study. The experimental arm is the group receiving ODM-201. The group receiving androgen-deprivation therapy (ADT) is included as an internal control.
- Trial name
- NCT02972060
- Testing
- ODM-201, ADT
- Where
- 12 sites in Belgium, France and 2 more
- Volunteers
- 61 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
This study addresses the global topic of treatment optimization, i.e. achieving similar benefit while reducing the duration of treatment, hence hoping to decrease the burden of side-effects, improve quality-of life and reduce…
- Trial name
- NCT05974774
- Testing
- iMAB, cMAB
- Where
- 9 sites in Denmark, France and 1 more
- Volunteers
- 1,600 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity
This was a phase III, randomized, double blind, multicenter, 2-arm study evaluating the efficacy and safety of amcenestrant compared with tamoxifen in participants with hormone receptor-positive early breast cancer who…
- Trial name
- AMEERA-6 (NCT05128773)
- Testing
- Amcenestrant, Tamoxifen
- Where
- 2 sites in Chile, China
- Volunteers
- 3 people
- Sponsor
- Sanofi
Colorectal Cancer Metastatic
LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)
Part I of this study is designed to identify the recommended phase 2 dose (RP2D) of the combination regimen of LY3200882/capecitabine as second line treatment in patients with 5-FU or capecitabine resistant CRC.
- Trial name
- NCT04031872
- Testing
- LY3200882
- Sponsor
- The Netherlands Cancer Institute
Any Stage of Lung Cancer (Any Histotype), Any Stage of Malignant Pleural Mesothelioma
SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access
SPECTAlung is a program aiming at screening patients with thoracic tumors to identify the molecular characteristics of their disease.
- Conditions
- Any Stage of Lung Cancer (Any Histotype), Any Stage of Malignant Pleural Mesothelioma, Any Stage of Any Thymic Malignancy
- Trial name
- SPECTAlung (NCT02214134)
- Testing
- Tumour markers testing
- Where
- 18 sites in Belgium, France and 7 more
- Volunteers
- 539 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Oropharyngeal Cancer, Supraglottic Squamous Cell Carcinoma
Study Assessing The "Best of" Radiotherapy vs the "Best of" Surgery in Patients With Oropharyngeal Carcinoma
Oropharyngeal Squamous Cell Carcinoma (OPSCC) arises in the soft palate, tonsils, base of tongue, pharyngeal wall, and the vallecula. Most of the patients with early stage OPSCC are usually cured.
- Conditions
- Oropharyngeal Cancer, Supraglottic Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
- Trial name
- Best Of (NCT02984410)
- Testing
- Intensity-Modulated Radiation Therapy (IMRT), Trans Oral Surgery (TOS)
- Where
- 32 sites in Belgium, France and 6 more
- Volunteers
- 112 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma
RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with combination chemotherapy may kill more tumor cells.
- Trial name
- NCT00002462
- Testing
- bleomycin sulfate, doxorubicin hydrochloride, mechlorethamine hydrochloride
- Where
- 56 sites in Belgium, Egypt and 7 more
- Volunteers
- 615 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00005584
- Testing
- bleomycin sulfate, ABVD regimen, BEACOPP regimen
- Where
- 121 sites in Belgium, France and 8 more
- Volunteers
- 1,649 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00049595
- Testing
- bleomycin sulfate, filgrastim, pegfilgrastim
- Where
- 140 sites in Australia, Belgium and 11 more
- Volunteers
- 552 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma
Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma
RATIONALE: Radiation therapy uses high-energy x-rays to kill cancer cells. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00379041
- Testing
- bleomycin sulfate, doxorubicin hydrochloride, mechlorethamine hydrochloride
- Volunteers
- 1,158 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Colon Cancer
Vinorelbine in Advanced BRAF-like Colon Cancer
Vecchione et al showed that suppression of RANBP2 results in mitotic defects only in BRAF-like colon cancer (CC) cells, which leads to cell death.
- Trial name
- EORTC1616 (NCT03482362)
- Testing
- Vinorelbine Tartrate
- Where
- Netherlands
- Volunteers
- 1 people
- Sponsor
- The Netherlands Cancer Institute
Uterine Sarcoma
IRCI Gynae Sarcomas, High Grade Uterine Sarcoma
This study aims to investigate a drug called Cabozantinib which belongs to a family of drugs that have effects on tumour growth, blood supply, invasion and spread.
- Trial name
- NCT01979393
- Testing
- Cabozantinib
- Where
- 15 sites in France, Italy and 3 more
- Volunteers
- 58 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Unresectable Stage III Melanoma, Stage IV Melanoma
Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib
This is a multicenter, 2-arm open-label, randomized comparative phase II study. The objective of this trial is to prospectively evaluate whether a sequential approach with an induction period of 12 weeks with encorafenib +…
- Trial name
- EBIN (NCT03235245)
- Testing
- Nivolumab + Ipilimumab, Encorafenib + Binimetinib
- Where
- 38 sites in Denmark, Finland and 7 more
- Volunteers
- 271 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer, Prostate Cancer
OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)
The goal of this clinical trial is to evaluate single-fraction metastases-directed SBRT in the broader radiation oncology community and to compare its safety and efficacy profile with the current Standard of Care (SoC) of…
- Conditions
- Breast Cancer, Prostate Cancer, NSCLC, Colorectal Cancer
- Trial name
- SPRINT (NCT06462963)
- Testing
- single-fraction SBRT, multiple-fraction SBRT
- Where
- 15 sites in Belgium, Italy and 2 more
- Volunteers
- 302 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Malignant Neoplasm of Stomach, Malignant Neoplasm of Cardio-esophageal Junction of Stomach
Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma
The purpose of this study is to find out whether either trastuzumab or the combination of trastuzumab and pertuzumab with standard chemotherapy shows more activity against gastro-oesophageal adenocarcinoma than standard…
- Conditions
- Malignant Neoplasm of Stomach, Malignant Neoplasm of Cardio-esophageal Junction of Stomach, Epidermal Growth Factor Receptor (EGFR) Protein Overexpression
- Trial name
- INNOVATION (NCT02205047)
- Testing
- Cisplatin, 5-fluorouracil or Capecitabine, Trastuzumab
- Where
- 48 sites in Belgium, Estonia and 11 more
- Volunteers
- 172 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC